Bronchiolitis: Protecting Your Baby’s Health
- Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms.Though, it can be severe in infants and young children, leading to bronchiolitis and...
- Two strategies have recently become available to help prevent RSV in infants: Beyfortus (nirsevimab) and Abrysvo (RSVpreF).
- Beyfortus is a monoclonal antibody that provides passive immunization against RSV.
“`html
beyfortus vs. Abrysvo: comparing RSV Prevention Strategies for Infants
Table of Contents
Published December 27, 2023, 11:40 AM PST. Updated as new data becomes available.
Understanding RSV and the Need for prevention
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms.Though, it can be severe in infants and young children, leading to bronchiolitis and pneumonia. RSV is the leading cause of hospitalization for infants in the United States, according to the Centers for Disease Control and Prevention ([CDC RSV Overview](https://www.cdc.gov/rsv/index.html)).
Two strategies have recently become available to help prevent RSV in infants: Beyfortus (nirsevimab) and Abrysvo (RSVpreF). Both aim to protect infants during their first RSV season, but they differ in their approach.
Beyfortus (Nirsevimab): Passive Immunization
Beyfortus is a monoclonal antibody that provides passive immunization against RSV. This means it delivers antibodies directly to the infant,offering immediate protection. It’s administered as a single intramuscular injection.
according to the French High Authority of Health (HAS), Beyfortus is generally preferred in specific situations (detailed below).
Abrysvo (RSVpreF): Active Immunization
Abrysvo is an RSV vaccine administered to pregnant individuals during the third trimester. This stimulates the mother’s immune system to produce antibodies that are then passed on to the baby, providing protection after birth. This is known as active immunization.
Data indicates that Abrysvo is associated with a higher risk of certain adverse events compared to Beyfortus. Specifically, Abrysvo was linked to a 42% increase in pediatric intensive care unit (PICU) admissions, a 44% increase in oxygen therapy use, and a 43% increase in intubations, compared to Beyfortus, according to the source material.
Effectiveness: A Close Comparison
Despite the differences in safety profiles,both Beyfortus and abrysvo demonstrate significant effectiveness,ranging between 65% and 85%,in reducing hospitalizations for bronchiolitis in infants. Both strategies have shown promising results in clinical trials and real-world studies.
| Prevention Strategy | Type of Immunization | Administration | Effectiveness (hospitalization Reduction) | Key Considerations |
|---|---|---|---|---|
| Beyfortus (Nirsevimab) | Passive | Single injection to infant | 65-85% | Preferred in certain high-risk cases (see below). |
| Abrysvo (RSVpreF) | Active | Vaccination of pregnant individual (3rd trimester) | 65-85% | Higher risk of certain adverse events; data limited
|